A. Varewijck

发表

Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir.

S. Lamberts, L. Hofland, J. Goudzwaard, 2010, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Serum Insulin Bioassay Reflects Insulin Sensitivity and Requirements in Type 1 Diabetes

C. Forsblom, P. Groop, J. Vendrell, 2017, The Journal of clinical endocrinology and metabolism.

Insulin receptor and IGF-I receptor Bioactivity in Health and Disease

A. Varewijck, 2013 .

Insulin and its analogues and their affinities for the IGF1 receptor.

A. Varewijck, J. Janssen, 2012, Endocrine-related cancer.

Insulin Analogs and Cancer: A Note of Caution

A. Varewijck, J. Janssen, 2014, Front. Endocrinol..

The introduction of the IDS-iSYS total IGF-1 assay may have far-reaching consequences for diagnosis and treatment of GH deficiency.

S. Lamberts, A. J. van der Lely, L. Hofland, 2015, The Journal of clinical endocrinology and metabolism.

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling

N. Tennagels, H. Yki-Järvinen, A. Varewijck, 2013, Diabetes.

Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling

D. Dimitrov, S. Lamberts, J. Frystyk, 2013, Molecular and Cellular Endocrinology.

The IGSF1 deficiency syndrome: characteristics of male and female patients.

R. Hennekam, M. Dattani, R. Hennekam, 2013, The Journal of clinical endocrinology and metabolism.

Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults.

S. Lamberts, A. J. van der Lely, L. Hofland, 2015, European journal of endocrinology.

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly

S. Lamberts, H. Yki-Järvinen, L. Hofland, 2012, Diabetologia.

Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy.

E. Fliers, W. Wiersinga, S. Lamberts, 2013, The Journal of clinical endocrinology and metabolism.

In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life

S. Lamberts, A. J. van der Lely, L. Hofland, 2014, Endocrine connections.

In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life

S. Lamberts, L. Hofland, S. Neggers, 2014, Endocrine connections.

IGF-IR Targeted Therapy: Past, Present and Future

A. Varewijck, J. Janssen, 2014, Front. Endocrinol..

Low circulating IGF-I bioactivity is associated with human longevity: Findings in centenarians’ offspring

D. Mari, C. Franceschi, G. Vitale, 2012, Aging.

IGF-I bioactivity better reflects growth hormone deficiency than total IGF-I.

S. Lamberts, L. Hofland, P. Uitterlinden, 2011, The Journal of clinical endocrinology and metabolism.

IGF-I bioactivity might reflect different aspects of quality of life than total IGF-I in GH-deficient patients during GH treatment.

S. Lamberts, L. Hofland, S. Neggers, 2013, The Journal of clinical endocrinology and metabolism.

The insulin-like growth factor-I receptor stimulating activity (IRSA) in health and disease.

M. Brugts, A. Varewijck, J. Janssen, 2019, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Disagreement in normative IGF‐I levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency

A. J. van der Lely, L. Hofland, S. Neggers, 2018, Clinical endocrinology.